Endocrine Disrupting Effects Of Butylated Hydroxyanisole (Bhabhabha - E320)

Authors

  • Anca Pop
  • Bela Kiss
  • Felicia Loghin

Keywords:

butylated hydroxyanisole, endocrine disrupting effect, safety concern

Abstract

    Butylated hydroxyanisole (BHA) is extensively used as antioxidant in foods, food packaging, cosmetics and pharmaceuticals. In the past years, it raised concerns regarding its possible endocrine disrupting effect. The existing in vitro studies indicate that BHA presents a weak estrogenic effect and also anti-androgenic properties while an in vivo study found it to have antiestrogenic properties.
    There is no sufficient data available at the moment to draw a conclusion regarding the safety of BHA when referring to its endocrine disrupting effect.
    Since a fraction of the population might be exposed to doses superior to the acceptable daily intake (ADI), it is important to gather more in vitro and in vivo data concerning the potential effects that BHA might have alone, but also in mixtures with natural hormones or other endocrine disrupting compounds.

Author Biography

Anca Pop, Department of Toxicology, Faculty of Pharmacy, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

bio

Downloads

Published

2014-02-14

How to Cite

1.
Pop A, Kiss B, Loghin F. Endocrine Disrupting Effects Of Butylated Hydroxyanisole (Bhabhabha - E320). Med Pharm Rep [Internet]. 2014 Feb. 14 [cited 2025 Oct. 6];86(1):16-20. Available from: https://medpharmareports.com/index.php/mpr/article/view/100

Issue

Section

Reviews